StreetInsider.com News Articles

TransCode Therapeutics CFO Tom Fitzgerald retires, replaced interim

Thu, 10 Sep 2026 16:13:02 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately, with John Tattory named as Interim Chief Financial Officer.

Fitzgerald has served as CFO since July 2018, during which time he helped lead the company through its initial public offering, the launch of its clinical program for lead product candidate TTX-MC138, and the acquisition of Polynoma and a license agreement with Oncolytics.

Philippe P. Calais, Ph.D., Chairman of the Board and CEO, said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key

TransCode Therapeutics CFO Tom Fitzgerald retires, replaced interim

Thu, 10 Sep 2026 16:13:02 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately, with John Tattory named as Interim Chief Financial Officer.

Philippe P. Calais, Ph.D., Chairman of the Board and CEO, said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key

TransCode Therapeutics CFO Tom Fitzgerald retires, replaced interim

Thu, 10 Sep 2026 16:13:02 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately, with John Tattory named as Interim Chief Financial Officer.

Philippe P. Calais, Ph.D., Chairman of the Board and CEO, said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key

TransCode Therapeutics CFO Tom Fitzgerald retires, replaced interim

Thu, 10 Sep 2026 16:13:02 -0400

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately, with John Tattory named as Interim Chief Financial Officer.

Philippe P. Calais, Ph.D., Chairman of the Board and CEO, said: "On behalf of the Board, I wish to thank Tom for his many years of dedicated service to the company and its key

TransCode Therapeutics Announces Leadership Transition

Thu, 10 Sep 2026 16:10:00 -0400

Tom Fitzgerald, Chief Financial Officer, Announces his Retirement

John Tattory, to become Interim Chief Financial Officer

BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald. Mr. Fitzgerald has served as the Chief Financial Officer of TransCode Therapeutics since July 2018, during which time he helped lead the company through its initial public offering, the launch of its clinical program

TransCode Therapeutics Announces Leadership Transition

Thu, 10 Sep 2026 16:10:00 -0400

Tom Fitzgerald, Chief Financial Officer, Announces his Retirement

John Tattory, to become Interim Chief Financial Officer

TransCode Therapeutics Announces Leadership Transition

Thu, 10 Sep 2026 16:10:00 -0400

Tom Fitzgerald, Chief Financial Officer, Announces his Retirement

John Tattory, to become Interim Chief Financial Officer

TransCode Therapeutics Announces Leadership Transition

Thu, 10 Sep 2026 16:10:00 -0400

Tom Fitzgerald, Chief Financial Officer, Announces his Retirement

John Tattory, to become Interim Chief Financial Officer

Form 8-K WINDTREE THERAPEUTICS For: Dec 23

Wed, 22 Jul 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260722/26797438.html

Form 8-K WINDTREE THERAPEUTICS For: Dec 23

Wed, 22 Jul 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260722/26797438.html

Form NT 10-K WINDTREE THERAPEUTICS For: Dec 31

Wed, 01 Apr 2026 11:57:00 -0400

si-local-file:///var/storage/secattach/20260401/26257123.html

Form NT 10-K WINDTREE THERAPEUTICS For: Dec 31

Wed, 01 Apr 2026 11:57:00 -0400

si-local-file:///var/storage/secattach/20260401/26257123.html

CommLoan Achieves Nationwide Regulatory Approval Across All 50 States

Tue, 17 Mar 2026 08:02:00 -0400

Company plans reverse merger with Windtree Therapeutics as it expands its AI-powered commercial lending marketplace

SCOTTSDALE, Ariz., March 17, 2026 /PRNewswire/ -- CommLoan, a commercial real estate lending technology company operating the first true AI-powered commercial mortgage lending marketplace, announced today that it has obtained the final approvals needed to operate and do business in all 50 states, without restriction.

CommLoan Achieves Nationwide Regulatory Approval Across All 50 States

Tue, 17 Mar 2026 08:02:00 -0400

Company plans reverse merger with Windtree Therapeutics as it expands its AI-powered commercial lending marketplace

CommLoan Achieves Nationwide Regulatory Approval Across All 50 States

Tue, 17 Mar 2026 08:02:00 -0400

Company plans reverse merger with Windtree Therapeutics as it expands its AI-powered commercial lending marketplace

CommLoan Achieves Nationwide Regulatory Approval Across All 50 States

Tue, 17 Mar 2026 08:02:00 -0400

Company plans reverse merger with Windtree Therapeutics as it expands its AI-powered commercial lending marketplace

Form 8-K WINDTREE THERAPEUTICS For: Jan 05

Wed, 07 Jan 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260107/25820938.html

Form 8-K WINDTREE THERAPEUTICS For: Jan 05

Wed, 07 Jan 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260107/25820938.html

Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates

Tue, 23 Dec 2025 09:00:00 -0400

Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues)

Windtree would receive a payment of $700,000 from Seismic Pharmaceutical Holdings contingent on a financing round resulting in gross cash proceeds of at least $10,000,000